Skip to main content

Table 1 Baseline characteristics of the studies included in this meta-analysis

From: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma

Study Country Sample size Mean age (years) Men/women Disease status Stages Intervention Chemotherapy regimen Study quality
Coiffier 2002 [22] Multiple countries 399 69.0 199/200 Previously untreated DLBCL I-IV Rituximab (375 mg per square meter, on day 1 of each of the eight cycles of CHOP) CHOP 4
Habermann 2006 [23] Multiple countries 546 69.5 273/273 Previously untreated DLBCL I-IV Rituximab (375 mg per square meter, 7 and 3 days before cycle 1, and 2 days before cycles 3, 5, and, if administered, 7) CHOP 3
Pfreundschuh 2006 [24] Multiple countries 823 47.0 478/345 Good-prognosis DLBCL I-IV Rituximab (375 mg per square meter given IV on days 1, 22, 43, 64, 85, and 106 of the chemotherapy regimen) CHOP 4
Avilés 2007 [25] Mexico 196 59.8 105/91 High-risk DLBCL III-IV Rituximab (375 mg per square meter) CEOP 2
Vellenga 2008 [26] The Netherlands 225 54.5 130/95 Relapsed/progressive DLBCL I-IV Rituximab (375 mg per square meter was administered on day 5 of the DHAP course or on day 6 of the VIM course) DHAP 1
Pfreundschuh 2008 [27] Germany 1222 68.3 650/572 Previously untreated DLBCL I-IV Bi-weekly dosing of rituximab (375 mg per square meter) CHOP 4
Avilés 2010 [28] Mexico 100 50.2 48/52 Refractory DLBCL III-IV Rituximab (375 mg per square meter day 1 IV every cycle) ESHAP 1
Vose 2013 [29] US 224 57.7 142/82 Relapsed DLBCL NA Rituximab (375 mg per square meter on days 19 and 12) or I-tositumomab (dosimetric dose of 5 mCi on day 19 and therapeutic total-body dose of 0.75 Gy on day 12) BEAM 4
Ketterer 2013 [30] France 222 49.2 139/83 Localized low-risk DLBCL I-II Rituximab (375 mg per square meter was administered on days 1, 15, 29, and 43 of the regimen) ACVBP 3
Seymour 2014 [31] Multiple countries 787 61.0 387/400 Previously untreated DLBCL I-III Bevacizumab (10 mg kg−1 q2w or 15 mg kg− 1 q3w) R-CHOP 2
Offner 2015 [32] Multiple countries 164 59.0 88/76 Previously untreated DLBCL I-IV Bortezomib 1.3 mg per square meter by IV on days 1, 4, 8, and 11 R-CHOP 3
Fayad 2015 [33] US 151 59.0 85/66 Relapsed DLBCL I-IV Dacetuzumab administered on days 1, 3, 8, and 15 R-ICE 3
Hu 2017 [34] China 144 49.4 98/46 DLBCL NA Rituximab (375 mg per square meter was administered every 2 months for 1 year) CHOP 2
van Imhoff 2017 [35] Multiple countries 445 57.0 272/173 Relapsed or Refractory DLBCL I-IV Ofatumumab 1000 mg or rituximab 375 mg per square meter was administered for a total of four infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 and 3 of DHAP) DHAP 3
Vitolo 2017 [36] Multiple countries 1418 62.0 752/666 Previously untreated advanced-stage DLBCL I-IV Obinutuzumab (1000 mg IV on days 1, 8, and 15 of cycle 1, and on day 1 of cycles 2 to 8) or rituximab (375 mg per square meter IV on day 1 of cycles 1 to 8) CHOP 4
Czuczman 2017 [37] Multiple countries 102 67.0 61/41 Relapsed or Refractory DLBCL NA lenalidomide (25 mg per day, 21 days of 28-day cycle) or rituximab (375 mg per square meter IV on days 1, 8, 15, and 22 of cycles 1 to 8) GEO 2
Leonard 2017 [38] Multiple countries 201 63.0 107/94 Previously untreated DLBCL I-IV Bortezomib 1.3 mg per square meter IV on days 1 and 4 R-CHOP 3
Younes 2009 [39] Multiple countries 838 62.0 447/391 Previously untreated non-GCB DLBCL I-IV Ibrutinib (560 mg per day orally) R-CHOP 4